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Pseudomonas aeruginosa and other Gram-negative bacteria are becoming increasingly resistant to current antibiotics and pose a major threat to patients with hospital-acquired infections, compromised immune systems, or chronic pulmonary infections ([@B1][@B2][@B4]). Unfortunately, the discovery of new agents targeting Gram-negative bacteria is especially challenging due to an impermeable, lipopolysaccharide (LPS)-laden, outer membrane, in addition to porin mutations and efflux pumps limiting intracellular drug accumulation ([@B5], [@B6]). Among the last-resort antibiotics currently being used to treat severe multidrug-resistant pseudomonal infections is the polymyxin class of cationic antimicrobial peptides, including polymyxin B and colistin (polymyxin E). Recently, the first-in-class antibiotic POL7080, which is currently in phase 3 clinical trials, was reported to have species-specific activity against P. aeruginosa by inhibiting the LPS transport protein LptD ([@B7][@B8][@B9]). The discovery of POL7080 (and its analogue POL7001) emerged from extensive chemical modifications of the cationic antimicrobial peptide protegrin-1 (PG-1), in which a beta-hairpin was introduced to create cyclized peptidomimetic analogues ([@B10], [@B11]). The mechanism of action of POL7080 and its analogues differs from that of other cationic antimicrobial peptides in several key ways. Polymyxins and PG-1 interact with LPS and exhibit broad-spectrum antimicrobial activity through self-promoted uptake across the outer membrane, followed by cell lysis through poorly defined mechanisms ([@B12][@B13][@B14]). The LptD inhibitors POL7080 and POL7001, however, have been reported to exhibit a nonlytic mechanism of action through LptD inhibition in P. aeruginosa exclusively ([@B7][@B8][@B9]).

To investigate the mechanisms of resistance to POL7080 and its analogues, we selected for spontaneously resistant P. aeruginosa PA14 mutants by plating mid-log cultures on lysogeny broth (LB) agar containing 1.6 μg/ml POL7001 (∼4 times the MIC on LB agar; detailed experimental protocols are outlined in the supplemental material). We isolated 6 independent mutants and confirmed their resistance to POL7080, POL7001, and PG-1 by adapting the broth microdilution method described previously ([@B15]). All clones were highly resistant to POL7080, with 4-fold to 32-fold MIC shifts relative to PA14 ([Table 1](#T1){ref-type="table"}), comparable to 4 POL7080-resistant clinical isolates reported previously ([@B16]). Because resistant clones were selected in LB, MIC assays were also performed in LB, yielding results comparable to those obtained in Mueller-Hinton broth (MHB) (see Table S1 in the supplemental material). All strains remained susceptible to conventional antipseudomonal antibiotics (Table S2). Whole-genome sequencing revealed 1 or 2 single-nucleotide polymorphisms (SNPs) in each mutant, relative to the wild-type (WT) parent PA14, and all 6 isolates carried a mutation in the common gene *pmrB* ([Table 1](#T1){ref-type="table"}). PmrB is a histidine kinase and the membrane-bound sensor in the PmrA-PmrB two-component regulatory system in Gram-negative bacteria. In response to low Mg^2+^ levels and periplasmic antimicrobial peptides, PmrB undergoes conformational changes in its histidine kinase and methyl-accepting protein (HAMP) domain, leading to autophosphorylation, phosphoryl group transfer to its cognate response regulator PmrA, and downstream activation of transcriptional programs regulating LPS modification ([@B17]). Interestingly, mutations in the PmrA-PmrB system have been implicated in polymyxin resistance through upregulation of the lipid A deacylase PagL and the *arnBCADTEF-ugd* operon, resulting in LPS modifications that reduce polymyxin binding to the cell surface ([@B18][@B19][@B29]). Notably, the mutant PA14-*pmrB*~G188S~ contained an amino acid substitution at the same site in the HAMP domain as reported previously for the colistin-resistant clinical strain PA1571-*pmrB*~G188D~, which was isolated from a cystic fibrosis patient and was found to have the PmrB substitution G188D ([@B22]). Therefore, we measured colistin activity against all 6 resistant mutants and found cross-resistance, with MIC shifts ranging from 4-fold to 32-fold ([Table 1](#T1){ref-type="table"}). We also tested the colistin-resistant strain PA1571-*pmrB*~G188D~ with POL7080 and found that it had 8-fold cross-resistance, relative to PA14 ([Table 1](#T1){ref-type="table"}).

###### 

Summary of resistant mutants sequenced after selection with POL7001

  Strain                 PA14 no.   Gene                                        SNP(s)            Protein change(s)                            Function                  MIC (μg/ml) in MHB (fold change)[^*a*^](#T1F1){ref-type="table-fn"}                             
  ---------------------- ---------- ------------------------------------------- ----------------- -------------------------------------------- ------------------------- --------------------------------------------------------------------- ----------- ------------- -------------
  Wild-type PA14                                                                                                                                                         0.050                                                                 0.050       1.3           0.44
  PA14-*pmrB*~L172del~   63160      *pmrB*                                      CGCT506C          L172del[^*b*^](#T1F2){ref-type="table-fn"}   Two-component system      1.6 (32)                                                              1.6 (32)    43 (32)       14 (32)
  PA14-*pmrB*~G188S~     63160      *pmrB*                                      G562A             G188S                                        Two-component system      0.40 (8)                                                              0.20 (4)    11 (8)        1.8 (4)
                         21890      *hypo*[^*c*^](#T1F3){ref-type="table-fn"}   T932G             V311G                                        Putative oxidoreductase                                                                                                   
  PA14-*pmrB*~V136L~     63160      *pmrB*                                      G406C             V136L                                        Two-component system      0.80 (16)                                                             0.40 (8)    \>43 (\>32)   3.5 (8)
                         43080      *vgrG14*                                    C1325A + C1330G   A442E + H444D                                Type VI secretion                                                                                                         
  PA14-*pmrB*~T132P~     63160      *pmrB*                                      A394C             T132P                                        Two-component system      0.40 (8)                                                              0.40 (8)    \>43 (\>32)   3.5 (8)
  PA14-*pmrB*~R155H~     63160      *pmrB*                                      G464A             R155H                                        Two-component system      1.6 (32)                                                              1.6 (32)    \>43 (\>32)   7.0 (16)
  PA14-*pmrB*~A330P~     63160      *pmrB*                                      G988C             A330P                                        Two-component system      0.80 (16)                                                             0.80 (16)   \>43 (\>32)   3.5 (8)
  PA1571-*pmrB*~G188D~   63160      *pmrB*                                      G563A             G188D                                        Two-component system      0.20 (4)                                                              0.40 (8)    10.8 (8)      \>56 (\>64)

The fold change in MIC, relative to PA14, is shown in parentheses.

In-frame deletion of L172.

Hypothetical protein.

To confirm that alterations in *pmrB* account for the observed resistance to POL7080 and colistin in PA14, we introduced a copy of the wild-type allele *pmrB*~WT~ and the resistant alleles *pmrB*~L172del~ and *pmrB*~G188S~, under the control of an arabinose promoter, into PA14 at the neutral *att*Tn*7* chromosomal site using the pUC18-derived mini-Tn*7* integration system ([@B30]). We also introduced the allele *pmrB*~G188D~, which was reported previously to confer colistin resistance ([@B22]), into the wild-type background. MIC assays in the presence of 0.25% (vol/vol) arabinose demonstrated that all three mutated *pmrB* alleles, but not the wild-type allele, conferred POL7080 and colistin resistance ([Table 2](#T2){ref-type="table"}). Because the PA14-*pmrB*~G188S~ mutant was only modestly resistant to POL7080 in MHB, we also determined MICs in LB, the medium in which the mutants were selected, which confirmed that all mutant alleles conferred POL7080 and colistin resistance (Table S3). Conversely, expression of the *pmrB*~WT~ allele in the resistant PA14-*pmrB*~L172del~ background did not restore POL7080 susceptibility, suggesting that resistant *pmrB* alleles were largely dominant over the wild-type allele.

###### 

MICs in MHB with 0.25% arabinose after introduction of second *pmrB* alleles into PA14 and *pmrB*~L172del~ backgrounds

  Background strain      *att*Tn*7* allele   MIC (μg/ml) (fold change)[^*a*^](#T2F1){ref-type="table-fn"}   
  ---------------------- ------------------- -------------------------------------------------------------- -----------
  PA14                                       0.05                                                           0.44
  PA14                   *pmrB*~WT~          0.10 (2)                                                       0.44 (1)
  PA14                   *pmrB*~L172del~     0.80 (16)                                                      1.8 (4)
  PA14                   *pmrB*~G188S~       0.10 (2)                                                       0.88 (2)
  PA14                   *pmrB*~G188D~       0.40 (8)                                                       1.8 (4)
  PA14-*pmrB*~L172del~                       1.6                                                            7.0
  PA14-*pmrB*~L172del~   *pmrB*~WT~          0.8 (0.5)                                                      3.5 (0.5)

The fold change in MIC, relative to the background strain, is indicated in parentheses.

We next performed whole transcriptome sequencing to investigate the role of *pmrA-pmrB* in response to LptD inhibitors. After extracting total RNA from mid-log PA14 cells treated with 0.2 μg/ml POL7001 (2 times the MIC), we prepared RNA-seq libraries using the RNA TagSeq protocol ([@B31]), sequenced samples on an Illumina NextSeq instrument, and analyzed the data using Burrows-Wheeler Aligner ([@B32]) for alignment and DESeq2 ([@B33]) to determine differential gene expression. We found that LPS modification genes, including *pmrA-pmrB*, the lipid A deacylase gene *pagL*, and the entire *arnBCADTEF-ugd* operon, which is responsible for adding 4-amino-4-deoxy-[l]{.smallcaps}-arabinose ([l]{.smallcaps}-Ara4N) to lipid A, were significantly upregulated in response to POL7001 ([Fig. 1A](#F1){ref-type="fig"}). The aminotransferase gene *arnB*, coding for the protein that catalyzes the final step in [l]{.smallcaps}-Ara4N addition, was among the most highly upregulated genes in the entire data set. We confirmed these findings with quantitative reverse transcription-PCR (qRT-PCR) after treating mid-log PA14 or resistant PA14-*pmrB*~L172del~ cells with either POL7080 or DMSO (control) ([Fig. 1B](#F1){ref-type="fig"}). Relative to the control, POL7080 significantly induced *pmrA*, *arnB*, and *pagL* expression in PA14 cells. Notably, *arnB* and *pmrA* transcript levels in untreated PA14-*pmrB*~L172del~ cells exceeded those in POL7080-treated PA14 cells. Together, these data reveal that a signature transcriptional program involving key LPS modification genes is constitutively upregulated in the resistant mutant PA14-*pmrB*~L172del~. These results reveal a cellular response to LptD inhibitors that mirrors the previously reported response to polymyxins, and they suggest a shared mechanism by which *pmrB* mutations confer cross-resistance between POL7080 and colistin.

![LPS modification genes upregulated in response to POL7001 and POL7080 treatment and constitutively expressed in the resistant PA14-*pmrB*~L172del~ strain. (A) RNA-seq data show log~2~(fold change) in sequencing reads for PA14 after treatment at 37°C for 100 min with POL7001, relative to the vehicle control. Bracketed genes are located within the same operon. Upregulated genes include the *pmrA-pmrB* two-component regulatory system genes, the lipid A deacylase gene *pagL*, and the *arnBCADTEF-ugd* operon. (B) After treatment of PA14 and resistant PA14-*pmrB*~L172del~ cells with POL7080 or dimethyl sulfoxide (DMSO) (control) at 37°C for 100 min, qRT-PCR data show log~2~(fold change) in LPS modification gene transcript levels (normalized to *rpoD* expression), relative to vehicle-treated PA14 cells. In all experiments, error bars represent standard errors of the mean of 3 biological replicates (*n* = 3). The coefficient of variance of raw triplicate measurements ranged from 0.5 to 8.4%. Asterisks indicate paired *t* test *P* values of \<0.03 for POL7080-treated PA14 cells versus vehicle-treated PA14-*pmrB*~L172del~ cells.](AAC.00511-19-f0001){#F1}

Mutations in *pmrB* are known to drive polymyxin resistance by [l]{.smallcaps}-Ara4N addition to LPS, thereby reducing drug binding to the cell surface ([@B18][@B19][@B29]). Therefore, we investigated whether *pmrB* mutations might mitigate POL7080 binding to the cell surface. We synthesized tetramethylrhodamine (TAMRA)-L27-11 (Fig. S1), a red fluorescent analogue of POL7080 with retained inhibitory activity (Table S4), to probe for differential uptake in PA14-*pmrB*~L172del~ cells, relative to PA14 cells, using confocal microscopy. After treatment of mid-log PA14 or PA14-*pmrB*~L172del~ cells with 1.4 μg/ml TAMRA-L27-11, the cells were washed, fixed with 4% paraformaldehyde, and stained with 4′,6-diamidino-2-phenylindole (DAPI) for nucleic acid visualization. Red-field and blue-field confocal microscopy showed comparable DAPI staining but \>3-fold reduction in TAMRA-L27-11 uptake in PA14-*pmrB*~L172del~ cells, relative to PA14 cells ([Fig. 2](#F2){ref-type="fig"}), indicating less efficient drug binding at the cell surface of the resistant mutant.

![Differential uptake of TAMRA-L27-11 by PA14 cells versus PA14-pmrB~L172del~ cells. (A) Red-field (left) and blue-field (right) confocal microscopy images of PA14 cells (top) and PA14-pmrB~L172del~ cells (bottom) show reduced TAMRA-L27-11 uptake in PA14-*pmrB*~L172del~ cells, relative to PA14 cells. All cells were DAPI stained after treatment with 1.4 μg/ml TAMRA-L27-11 for 120 min. (B) Average fluorescence intensities of TAMRA (red bars) and DAPI (blue bars) were calculated for PA14 cells (solid bars) (*n* = 22 cells) and resistant PA14-*pmrB*~L172del~ cells (hatched bars) (*n* = 21 cells) using ImageJ software. The figure depicts a representative replicate from 3 independent experiments. Error bars represent standard errors of the mean, and asterisks indicate unpaired *t* test *P* values of \<0.0001 for PA14 cells versus PA14-*pmrB*~L172del~ cells after TAMRA-L27-11 treatment.](AAC.00511-19-f0002){#F2}

In summary, we report a series of *pmrB* mutations that confer high-level resistance to POL7080 and moderate cross-resistance to colistin. Expression analysis and confocal microscopy data support a resistance mechanism in which *pmrB* mutations upregulate the *arnBCADTEF-ugd* operon. These data align well with known mechanisms of resistance to polymyxins, in which upregulation of the *arn* operon has been shown to result in LPS modification with [l]{.smallcaps}-Ara4N reducing drug binding to the cell surface ([@B21][@B22][@B23]). Altogether, our findings suggest that preexisting colistin resistance may limit the utility of POL7080 in a subset of highly resistant P. aeruginosa cases and exposure to POL7080, if it is successfully developed, could inadvertently drive cross-resistance to colistin and other polymyxins.

Supplementary Material
======================

###### Supplemental file 1

Supplemental material for this article may be found at <https://doi.org/10.1128/AAC.00511-19>.
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